NTRK1 and cancer: Interestingly, data mined from the Cancer Therapeutics Response Portal (CTRP) 37 via GSCA indicate that BEX4 expression negatively correlates with sensitivity to multiple receptor tyrosine kinases (lenvatinib, axitinib, and AZD4547) (Figure S4D).